Other OTC - Delayed Quote USD

Roche Holding AG (RHHBF)

254.51 -18.89 (-6.91%)
As of 10:09 AM EDT. Market Open.
Loading Chart for RHHBF
DELL
  • Previous Close 273.40
  • Open 254.51
  • Bid --
  • Ask --
  • Day's Range 254.51 - 254.51
  • 52 Week Range 243.42 - 354.00
  • Volume 50
  • Avg. Volume 220
  • Market Cap (intraday) 179.505B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 16.22
  • EPS (TTM) 15.69
  • Earnings Date --
  • Forward Dividend & Yield 10.86 (3.97%)
  • Ex-Dividend Date Mar 14, 2024
  • 1y Target Est --

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

www.roche.com

103,605

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RHHBF

Performance Overview: RHHBF

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RHHBF
14.81%
MSCI WORLD
5.23%

1-Year Return

RHHBF
18.81%
MSCI WORLD
19.55%

3-Year Return

RHHBF
21.47%
MSCI WORLD
0.00%

5-Year Return

RHHBF
16.74%
MSCI WORLD
54.01%

Compare To: RHHBF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RHHBF

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    192.83B

  • Enterprise Value

    214.99B

  • Trailing P/E

    17.42

  • Forward P/E

    14.18

  • PEG Ratio (5yr expected)

    1.69

  • Price/Sales (ttm)

    3.32

  • Price/Book (mrq)

    6.78

  • Enterprise Value/Revenue

    3.56

  • Enterprise Value/EBITDA

    11.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.02%

  • Return on Assets (ttm)

    12.44%

  • Return on Equity (ttm)

    37.86%

  • Revenue (ttm)

    60.44B

  • Net Income Avi to Common (ttm)

    11.5B

  • Diluted EPS (ttm)

    15.69

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.51B

  • Total Debt/Equity (mrq)

    92.75%

  • Levered Free Cash Flow (ttm)

    8.6B

Research Analysis: RHHBF

Analyst Price Targets

 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: RHHBF

People Also Watch